Aethlon Medical
AEMD

$0.3477

10.02%

Market Cap: $4.85M

About: Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.

Employees: 14

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,686 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

80% more funds holding

Funds holding: 10 [Q1] → 18 (+8) [Q2]

2% more capital invested

Capital invested by funds: $87.5K [Q1] → $89.2K (+$1.7K) [Q2]

0.02% less ownership

Funds ownership: 1.99% [Q1] → 1.96% (-0.02%) [Q2]

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$7

1,913%

upside

Avg. target

$7

1,913%

upside

High target

$7

1,913%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Vernon Bernardino

40% 1-year accuracy

20 / 50 met price target

1,913%upside

$7

Buy

Maintained

24 Jun 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about AEMD published over the past 30 days

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys

Results Support Future Study of the Hemopurifier® as Part of a Machine Perfusion Circuit to Further Assess its Association with Function of Retrieved Kidneys SAN DIEGO , Aug. 27, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the publication in preprint of an in vitro study in bioRxiv on August 24, 2024, entitled, "The Hemopurifier® Removes Extracellular Vesicles and microRNAs From Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys." Aethlon Medical's Hemopurifier® is a therapeutic blood filtration system designed to bind and remove harmful exosomes and life-threatening viruses from blood and other biological fluids, qualities which have potential applications in oncology and infectious diseases, as well as in the organ transplant setting.

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys

Aethlon Medical, Inc. (AEMD) Q1 2025 Earnings Call Transcript

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q1 2025 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Michael Miller - Investor Relations, Rx Communications James Frakes - Interim Chief Executive Officer & Chief Financial Officer Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Operator Good day, and welcome to the Aethlon Medical Fiscal First Quarter 2025 Earnings and Corporate Update Conference Call. All participants will be in listen-only mode.

Aethlon Medical, Inc. (AEMD) Q1 2025 Earnings Call Transcript

Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update

Received Two Australian Ethics Committee Approvals for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies; Expects to Open Patient Enrollment in October of 2024 Achieved Significant 24% Reduction in Fiscal First Quarter Operating Expenses Compared to the Same Period in 2023 Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Aug. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal first quarter ended June 30, 2024 and provided an update on recent developments.

Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update

The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 12, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology issues a snapshot on recent news and developments for the treatment of solid cancer tumors, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article at Investorideas.com https://www.investorideas.com/News/2024/biotech/08120Cancer-Battle.asp The Brainy Insights estimates that the USD 222.71 Billion solid tumor therapeutics market will reach USD 885.44 Billion by 2033.

The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors

Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial

Bellberry Human Research Ethics Committee Granted Full Ethics Approval to the Pindara Private Hospital for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , Aug. 12, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that, on August 6, 2024, the Bellberry Human Research Ethics Committee (BHREC) granted full ethics approval to the Pindara Private Hospital for a safety, feasibility and dose-finding clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Merck's Keytruda® (pembrolizumab) or Bristol Myers Squibb's Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The approval is valid for one year, until August 6, 2025.

Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial

Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024

SAN DIEGO , Aug. 6, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal first quarter ended June 30, 2024, at 4:15 p.m. ET on Wednesday, August 14, 2024.

Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024

Aethlon Medical, Inc. (AEMD) Q4 2024 Earnings Call Transcript

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q4 2024 Earnings Conference Call June 27, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications, IR James Frakes - Interim CEO and CFO Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Operator Good day and welcome to the Aethlon Medical Fiscal Year End of 2024 Earnings Conference Call. All participants will be in a listen-only mode.

Aethlon Medical, Inc. (AEMD) Q4 2024 Earnings Call Transcript

Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update

Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , June 27, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2024 and provided an update on recent developments.

Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update

Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024

SAN DIEGO , June 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal year ended March 31, 2024, at 4:15 p.m. ET on Thursday, June 27, 2024.

Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024

What's Next in Treatments for Cancer Patients with Solid Tumors?

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 20, 2024) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future treatment of solid cancer tumors, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article on Investorideas.com https://www.investorideas.com/News/2024/biotech/06200Treatments-for-Cancer-Patients-with-Solid-Tumors.asp Research released this year predicts, "The solid tumor therapeutics market size will grow from USD 222.71 Billion in 2023 to USD 885.44 Billion in 10 years.

What's Next in Treatments for Cancer Patients with Solid Tumors?

See News Rankings